Get to know our clinical trials
Phase 3 clinical trial, to compare the efficacy and safety of MK-2870 in monotherapy versus physician's choice treatment as second-line therapy in participants with recurrent or metastatic cervical cancer.
THE MAIN OBJECTIVE IS TO EVALUATE THE SAFETY OF MK-2870.
Technical Summary
- PHASE 3, RANDOMIZED, ACTIVE TREATMENT-COMPARATIVE, UNBLINDED, MULTICENTER, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF MK-2870 IN MONOTHERAPY VERSUS TREATMENT OF PHYSICIAN'S CHOICE AS SECOND-LINE THERAPY IN PARTICIPANTS WITH RECURRENT OR METASTATIC CERVICAL CANCER (TROFUSE-020/GOG-3101/ENGOT-CX20).
- Code EudraCT: 2023-508323-12
- Protocol number: MK-2870-020
- Promoter: Merck Sharp & Dohme, S.A.
- Molecule/Drug: MK-2870
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.